Determining the relationship between the function of an isolated protein and the function of that protein in a complex cellular environment is a significant analytical endeavor. Due to the time and cost associated with developing an enzyme linked immunoassay (ELISA), mass spectrometric approaches are playing an increasingly large role in protein analyses. Furthermore, mass spectrometric methods enable detection of isoform variations and post-translational modifications; identification of these features being key to an understanding of protein function and activity.
However, proteins often exist in complex cellular environments and the most important component of MS analyses are often the preceding separation processes. Unfortunately many approaches are complex, multifaceted, and often irreproducible. The NCI's Clinical Proteomics Technology Assessment for Cancer Network (CPTAC) was created to address these issues. This program provided Purdue Professor and Perfinity Founder Fred Regnier, Ph. D. key insights into the field's best practices and unmet needs. Central to the CPTAC focus was the use of an immunoaffinity enrichment to purify samples and maximize the sensitivity of the corresponding liquid chromatography tandem mass spectrometry measurements. However, Professor Regnier found that integration of multiple sample preparation steps could enable labs to maximize the amount of quality data they can generate.
Taking the steps to create an automated total solution Perfinity developed the Perfinity Workstation that not only performs immunoaffinity enrichment, but also buffer exchange, proteolysis and desalting steps. It is worth noting that these steps can be performed in less than 10 minutes on the Perfinity platform. Despite being a dramatic shift away from component based methods this technology has been well received by labs seeking to standardize and automate workflows, freeing up resources to focus on other aspects of assay development.
For more information about Perfinity and the automated total solution please visit the site: http://www.perfinity.com/.
The inclusion of industry news in the eProtein newsletter does not imply recommendation or endorsement by the National Cancer Institute, National Institutes of Health.